ES2938089T3 - Tubos de extracción de sangre al vacío que contienen inhibidores de proteasa para la evaluación de la activación del sistema de contacto - Google Patents

Tubos de extracción de sangre al vacío que contienen inhibidores de proteasa para la evaluación de la activación del sistema de contacto Download PDF

Info

Publication number
ES2938089T3
ES2938089T3 ES16757774T ES16757774T ES2938089T3 ES 2938089 T3 ES2938089 T3 ES 2938089T3 ES 16757774 T ES16757774 T ES 16757774T ES 16757774 T ES16757774 T ES 16757774T ES 2938089 T3 ES2938089 T3 ES 2938089T3
Authority
ES
Spain
Prior art keywords
subject
contact system
drug
blood collection
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16757774T
Other languages
English (en)
Spanish (es)
Inventor
Daniel Sexton
Ryan Faucette
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2938089T3 publication Critical patent/ES2938089T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/153—Devices specially adapted for taking samples of venous or arterial blood, e.g. with syringes
    • A61B5/154—Devices using pre-evacuated means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/150007—Details
    • A61B5/150015—Source of blood
    • A61B5/15003—Source of blood for venous or arterial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/150007—Details
    • A61B5/150755—Blood sample preparation for further analysis, e.g. by separating blood components or by mixing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/508—Rigid containers without fluid transport within
    • B01L3/5082—Test tubes per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/16—Reagents, handling or storing thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0832—Geometry, shape and general structure cylindrical, tube shaped
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Clinical Laboratory Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES16757774T 2015-08-13 2016-08-12 Tubos de extracción de sangre al vacío que contienen inhibidores de proteasa para la evaluación de la activación del sistema de contacto Active ES2938089T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562204644P 2015-08-13 2015-08-13
US201562214308P 2015-09-04 2015-09-04
PCT/US2016/046681 WO2017027771A1 (en) 2015-08-13 2016-08-12 Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation

Publications (1)

Publication Number Publication Date
ES2938089T3 true ES2938089T3 (es) 2023-04-04

Family

ID=56802683

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16757774T Active ES2938089T3 (es) 2015-08-13 2016-08-12 Tubos de extracción de sangre al vacío que contienen inhibidores de proteasa para la evaluación de la activación del sistema de contacto

Country Status (13)

Country Link
US (3) US10870115B2 (https=)
EP (3) EP3909509B1 (https=)
JP (4) JP6907188B2 (https=)
KR (2) KR102777762B1 (https=)
CN (2) CN116196995A (https=)
AU (2) AU2016306653B2 (https=)
BR (1) BR112018002742B1 (https=)
CO (1) CO2018002531A2 (https=)
EA (1) EA201890478A1 (https=)
ES (1) ES2938089T3 (https=)
IL (3) IL295914B2 (https=)
MX (2) MX2018001786A (https=)
WO (1) WO2017027771A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6907188B2 (ja) 2015-08-13 2021-07-21 ダイアックス コーポレーション 接触系活性化の評価のためのプロテアーゼ阻害剤を含む真空採血管
US11340237B2 (en) 2016-09-16 2022-05-24 Takeda Pharmaceutical Company Limited Metabolite biomarkers for diseases associated with the contact activation system
EP4548103A2 (en) 2022-06-30 2025-05-07 Takeda Pharmaceutical Company Limited Protein biomarkers for lanadelumab treatment

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047323A (en) 1986-01-22 1991-09-10 Temple University Of The Commonwealth System Of Higher Education Method for detecting human kininogen using monoclonal antibodies thereto
WO1995021601A2 (en) 1994-01-11 1995-08-17 Protein Engineering Corporation Kallikrein-inhibiting 'kunitz domain' proteins and analogues thereof
JP3622286B2 (ja) * 1995-09-01 2005-02-23 日東紡績株式会社 α２ −プラスミンインヒビタ−の測定方法及び測定試 薬
US5789261A (en) * 1996-10-30 1998-08-04 Temple University Of The Commonwealth System Of Higher Education Solid phase immunoassay
SK12572001A3 (sk) * 1999-03-15 2002-03-05 Takeda Chemical Industries, Ltd. Proteín, peptid, protilátka, spôsob výroby a farmaceutický prostriedok
JP4496407B2 (ja) 2002-05-13 2010-07-07 ベクトン・ディキンソン・アンド・カンパニー プロテアーゼ阻害剤試料採取システム
SE0202880D0 (sv) * 2002-07-26 2002-09-30 Wieslab Ab Complement system deficiency assay
US8603345B2 (en) * 2003-02-13 2013-12-10 Becton, Dickinson And Company Devices for component removal during blood collection, and uses thereof
US7138412B2 (en) 2003-03-11 2006-11-21 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives useful as serine protease inhibitors
US20050124965A1 (en) * 2003-12-08 2005-06-09 Becton, Dickinson And Company Phosphatase inhibitor sample collection system
WO2005084317A2 (en) * 2004-03-01 2005-09-15 Board Of Regents, The University Of Texas System Dimeric small molecule potentiators of apoptosis
EP1828152B1 (en) 2004-12-08 2008-08-20 Bristol-Myers Squibb Company Heterocyclic compounds as inhibitors of factor viia
US20060183771A1 (en) 2005-02-17 2006-08-17 Seiffert Dietmar A Novel combination of selective factor VIIa and/or factor XIa inhibitors and selective plasma kallikrein inhibitors
US9957569B2 (en) * 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
ES2336622T3 (es) 2006-06-06 2010-04-14 F. Hoffmann-La Roche Ag Recipiente de recogida de sangre total lista para usar.
EP1890155A1 (en) * 2006-08-17 2008-02-20 F. Hoffmann-Roche AG Methods and means for determining platelet function and diagnosing platelet-related and cardiovascular disorders
US20080286818A1 (en) * 2007-05-18 2008-11-20 Datwyler Saul A Blood sample handling methods for improved assays for myeloperoxidase
JP2010528647A (ja) * 2007-06-06 2010-08-26 ドマンティス リミテッド ポリペプチド、抗体可変ドメインおよびアンタゴニスト
WO2009022001A1 (en) * 2007-08-16 2009-02-19 Novartis Ag Improvement of drug tolerance in immunogenicity testing
WO2009026539A1 (en) * 2007-08-23 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
US8283160B2 (en) * 2007-09-11 2012-10-09 Frey Ii William H Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system
US9482677B2 (en) 2008-02-27 2016-11-01 Scios Inc. Method, composition and device for sampling natriuretic peptides in a biological fluid
US7985188B2 (en) 2009-05-13 2011-07-26 Cv Holdings Llc Vessel, coating, inspection and processing apparatus
WO2011024172A2 (en) * 2009-08-27 2011-03-03 Technion Research & Development Foundation Ltd. Liposomal compositions and uses of same
WO2011033046A1 (en) 2009-09-18 2011-03-24 Probiodrug Ag Novel assay for the detection of amyloid beta peptides
CN102740888B (zh) * 2009-11-24 2016-10-12 奥尔德生物制药公司 Il-6抗体及其用途
NZ609363A (en) 2010-10-18 2015-04-24 Nestec Sa Methods for determining anti-drug antibody isotypes
KR102320178B1 (ko) * 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
CA2828761C (en) 2011-03-04 2017-04-04 Becton, Dickinson And Company Blood collection device containing lysophospholipase inhibitor
JP6189754B2 (ja) * 2011-03-04 2017-08-30 イントレキソン コーポレーション タンパク質を条件的に発現するベクター
US9352016B2 (en) * 2011-03-09 2016-05-31 Csl Behring Gmbh Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces
GB201114017D0 (en) 2011-08-15 2011-09-28 Univ Dundee Inhibitors against endosomal/ysosomal enzymes
BR112014018970A8 (pt) * 2012-02-02 2017-07-11 Becton Dickinson Co Dispositivos de coleta de amostra com agentes de estabilização sanguínea
RU2015136025A (ru) 2013-02-01 2017-03-06 Бектон, Дикинсон энд Кампани Устройства для сбора крови, содержащие добавки, ингибирующие контактный путь свертывания крови
CA2916399C (en) 2013-06-28 2022-08-02 Marc Nolte Combination therapy using a factor xii inhibitor and a c1-inhibitor
WO2015061183A1 (en) 2013-10-21 2015-04-30 Dyax Corp. Assays for determining plasma kallikrein system biomarkers
JP6907188B2 (ja) * 2015-08-13 2021-07-21 ダイアックス コーポレーション 接触系活性化の評価のためのプロテアーゼ阻害剤を含む真空採血管

Also Published As

Publication number Publication date
JP7829634B2 (ja) 2026-03-13
JP6907188B2 (ja) 2021-07-21
CN108135547A (zh) 2018-06-08
JP7242765B2 (ja) 2023-03-20
JP2023078232A (ja) 2023-06-06
NZ739623A (en) 2023-09-29
US20190022641A1 (en) 2019-01-24
EP4574040A2 (en) 2025-06-25
AU2021215261B2 (en) 2023-10-12
EA201890478A1 (ru) 2018-07-31
IL257209B (en) 2022-09-01
IL311909B1 (en) 2025-11-01
HK1255461A1 (en) 2019-08-16
WO2017027771A1 (en) 2017-02-16
CO2018002531A2 (es) 2018-06-12
EP3334343B1 (en) 2022-10-19
KR102777762B1 (ko) 2025-03-11
IL295914B1 (en) 2024-05-01
KR20250035045A (ko) 2025-03-11
US20230182139A1 (en) 2023-06-15
JP2024150720A (ja) 2024-10-23
BR112018002742B1 (pt) 2023-05-16
EP3909509A1 (en) 2021-11-17
EP4574040A3 (en) 2025-08-27
AU2016306653A1 (en) 2018-02-22
CN108135547B (zh) 2023-01-10
IL257209A (en) 2018-04-30
MX2022014713A (es) 2022-12-16
US10870115B2 (en) 2020-12-22
IL311909B2 (en) 2026-03-01
IL311909A (en) 2024-06-01
MX2018001786A (es) 2018-06-06
US11826758B2 (en) 2023-11-28
EP3909509B1 (en) 2025-04-09
EP3334343A1 (en) 2018-06-20
US11458477B2 (en) 2022-10-04
IL295914B2 (en) 2024-09-01
AU2016306653B2 (en) 2021-05-13
CN116196995A (zh) 2023-06-02
US20210322972A1 (en) 2021-10-21
AU2021215261A1 (en) 2021-09-02
BR112018002742A2 (https=) 2018-10-02
CA2995457A1 (en) 2017-02-16
JP2018532100A (ja) 2018-11-01
JP2021164678A (ja) 2021-10-14
IL295914A (en) 2022-10-01
KR20180100107A (ko) 2018-09-07

Similar Documents

Publication Publication Date Title
JP7829634B2 (ja) 接触系活性化の評価のためのプロテアーゼ阻害剤を含む真空採血管
Keane et al. Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organs
ES2745099T3 (es) Procedimiento de diagnóstico de hiperaldosteronismo primario
HK40128524A (en) Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
CA2995457C (en) Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
HK1255461B (en) Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
Lipchick et al. Selective abrogation of S6K2 maps lipid homeostasis as a survival vulnerability in MAPKi-resistant NRASMUT melanoma
HK40061902B (en) Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
NZ739623B2 (en) Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
EA040036B1 (ru) Вакуумные пробирки для сбора крови, содержащие ингибиторы протеазы, для оценки активации контактной системы
Zhu Metadherin Functions As A Laminin Receptor That Is Essential For Metastasis and Is Associated With Poor Survival In Osteosarcoma
BR112018012165B1 (pt) Método para detectar cininogênio de alto peso molecular (hmwk) clivado, método para diferenciar hmwk completo e hmwk clivado, e método para identificar um sujeito com, ou correndo o risco de ter, angioedema hereditário (hae)